On Jan. 15, 2021, VBI Vaccines announced that results from a Phase 4 study of VBIﾒs prophylactic 3-antigen Hepatitis B virus (HBV) vaccine in younger adults were published in Vaccine, a journal publication from Elsevier. The study was designed to evaluate the immunogenicity of VBIﾒs 3-antigen HBV vaccine in support of the qualification of that batch as a new reference standard for vaccine release to the Israeli market, where VBIﾒs vaccine is available as Sci-B-Vacﾮ.